Valuation : Wockhardt Limited

Market Cap 321B 3.36B 2.9B 2.72B 2.48B 4.67B 4.69B 32.22B 12.57B 162B 12.62B 12.35B 538B P/E 2025
-472x
P/E 2026 89.7x
Enterprise Value 337B 3.52B 3.04B 2.85B 2.6B 4.9B 4.91B 33.78B 13.18B 170B 13.23B 12.94B 564B EV / Sales 2025
8.1x
EV / Sales 2026 5.97x
Free-Float
48.98%
Yield 2025 *
-
Yield 2026 -
1 day+0.77%
1 week+4.81%
Current month+0.89%
1 month+4.60%
3 months+11.64%
6 months+45.17%
Current year+36.71%
1 week 1,867.7
Extreme 1867.7
2,045
1 month 1,814.4
Extreme 1814.4
2,067.7
Current year 1,086.7
Extreme 1086.7
2,422.3
1 year 1,086.7
Extreme 1086.7
2,422.3
3 years 213.25
Extreme 213.25
2,422.3
5 years 145.15
Extreme 145.15
2,422.3
10 years 145.15
Extreme 145.15
2,422.3
Manager TitleAgeSince
Chief Executive Officer 53 2009-03-31
Director of Finance/CFO - 2022-02-28
Chief Tech/Sci/R&D Officer - 1998-04-30
Director TitleAgeSince
Chairman 83 2009-11-05
Director/Board Member 53 2009-11-05
Director/Board Member 55 1996-06-30
Change 5-day change 1-year change 3-year change Capi.($)
+0.77%+4.81%+38.62%+759.24% 3.36B
+0.35%+0.93%+21.08%+71.89% 48.2B
-0.08%-0.21%+55.27%+121.68% 39.97B
+0.15%+6.34%+21.70%+87.77% 12.43B
+0.25%-0.61%-9.92%+15.84% 12.03B
+0.19%0.00%+30.00%+147.62% 9.35B
+0.07%+3.80%+27.45%+46.12% 7.75B
+2.24%+8.50%+29.85%+227.84% 7.43B
+0.04%+0.37%+48.15%-11.95% 7.22B
-0.53%-1.53%-34.29%+19.67% 5.3B
Average +0.35%+2.57%+22.79%+148.57% 15.3B
Weighted average by Cap. +0.25%+1.49%+28.66%+102.00%

Financials

2025 2026
Net sales 30.35B 318M 274M 257M 234M 441M 443M 3.04B 1.19B 15.32B 1.19B 1.17B 50.8B 34.62B 362M 312M 293M 267M 503M 505M 3.47B 1.35B 17.48B 1.36B 1.33B 57.95B
Net income -470M -4.92M -4.24M -3.97M -3.63M -6.83M -6.85M -47.14M -18.39M -237M -18.46M -18.06M -787M 2.13B 22.29M 19.2M 18.01M 16.44M 30.96M 31.06M 214M 83.35M 1.08B 83.67M 81.85M 3.57B
Net Debt 14.33B 150M 129M 121M 111M 208M 209M 1.44B 561M 7.23B 563M 551M 23.99B 15.53B 162M 140M 131M 120M 226M 226M 1.56B 608M 7.84B 610M 597M 25.99B
Logo Wockhardt Limited
Wockhardt Limited is a research-based global pharmaceutical and biotech company. The Company is engaged in the pharmaceutical business. It focuses on the unmet need for antibacterial drugs that are effective against the menace of untreatable superbugs. It manufactures and supplies branded and generic finished formulations, as well as intermediate products like active pharmaceutical ingredients (APIs), worldwide. The Company’s products in India include EMROK, MERIWOK, REINVEXIN, ERLISO, METHYCOBAL 500 MCG 15T, METHYCOBAL INJ 1 ML, METHYCOBAL D 10T, HAPID 10C, PROXYFEN NANO GEL, LIVATIRA 500 10T NEW PACK, LIVATIRA INJ 5 ml, GABAWOK NT 100MG 15T, GABAWOK NT 400MG 15T, ETOBRIX 90 MG 10C, ETOBRIX TH 4 10C, ETOBRIX P 10T, GLARZEN 100IU, TERITIDE, GLIMADAY HS, GLIMADAY FORTE-2, GLIMADAY FORTE-1, GLIMADAY FORTE 3, GLIMADAY 2 mg, GLIMADAY 1 mg, MOPADAY FORTE, INOGLA, WEPOX 4000 IU 1ML, MYCORAL M, Val 450, OKERON INJ 100MCG 1ML, DARBOTIN 40, and DARBOTIN 60.
Employees
2,564
Date Price Change Volume
26-08-28 ₹1,977.10 +0.77% 1,581,060
26-08-27 ₹1,962.00 +4.25% 1,210,241
26-08-26 ₹1,882.10 -0.92% 310,259
26-08-25 ₹1,899.60 -0.07% 241,579
26-08-24 ₹1,901.00 +0.78% 306,988
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. WOCKPHARMA Stock